NCT06444204View on ClinicalTrials.gov

A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

March 23, 2021

Study Completion Date

March 23, 2021

Conditions

Hepatic Function AbnormalHealthy Volunteers

Interventions

DRUG

Rilzabrutinib

Rilzabrutinib tablet administered orally

Trial Locations (2)

32809

Investigational Site Number: 0001, Orlando

33014

Investigational Site Number: 0002, Miami

All Listed Sponsors

lead

Principia Biopharma, a Sanofi Company

INDUSTRY

NCT06444204 - A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008) | Biotech Hunter | Biotech Hunter